Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes

PURPOSE: Rearranged during transfection (RET) fusions are important genetic drivers in non-small cell lung cancer (NSCLC). Selective RET inhibitors are setting a new paradigm in RET-driven NSCLC. However, the real-world treatment patterns, outcomes and toxicity remain largely unknown. METHODS: Data...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chang, Wei, Xue-Wu, Zhang, Yi-Chen, Chen, Zhi-Hong, Xu, Chong-Rui, Zheng, Ming-Ying, Yang, Jin-Ji, Zhang, Xu-Chao, Zhou, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314840/
https://www.ncbi.nlm.nih.gov/pubmed/35838839
http://dx.doi.org/10.1007/s00432-022-04188-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314840/
https://www.ncbi.nlm.nih.gov/pubmed/35838839
http://dx.doi.org/10.1007/s00432-022-04188-7

Ejemplares similares